Nā huahana

Hiki i ka Niacin (nicotinic acid) ma ke ʻano he monotherapy ke hōʻemi i ka pilikia o ka maʻi vascular, akā paʻa mau kāna hana o ka hana, a ʻaʻole paha e hilinaʻi i nā hopena hoʻololi lipid systemic.Ua hōʻike ʻia ʻo Niacin i kēia manawa e hoʻomaikaʻi i ka hana endothelial a me ka hoʻōla hou ʻana o ka vascular, kūʻokoʻa i ka hoʻoponopono ʻana i ka dyslipidemia, i nā hiʻohiʻona rodent o ka hōʻeha vascular a me ka maʻi metabolic.Ma ke ʻano he biosynthetic precursor no NAD (+), hiki i ka niacin ke loaʻa i kēia mau pōmaikaʻi vascular ma o NAD (+) -dependent, sirtuin (SIRT) i hoʻopili ʻia.ʻO kahi ʻē aʻe, hiki i ka niacin ke hana ma o kāna mea loaʻa, GPR109A, e hoʻoikaika i ka hana endothelial, ʻoiai ʻaʻole ʻike ʻia nā cell endothelial e hōʻike i kēia mea loaʻa.Manaʻo mākou e hoʻomaikaʻi pololei ʻo niacin i ka hana o ka endothelial cell i ka wā e ʻike ai i nā kūlana lipotoxic a ʻimi e hoʻoholo i nā ʻano hana hiki ke komo. haʻahaʻa haʻahaʻa o ka niacin (10 μM), a i ʻole nicotinamide mononucleotide (NMN) (1 μM), he NAD (+) precursor pololei.ʻOiai ua hoʻomaikaʻi ʻo niacin a me NMN i ka hoʻokumu ʻana o ka tube HMVEC i ka wā o ka hoʻonui ʻana i ka palmitate, ʻo NMN wale nō i hoʻonui i ka cellular NAD (+) a me ka hana SIRT1.Ua ʻike hou mākou ua hōʻike ʻo HMVEC i ka GRP109A.ʻO ka hoʻoulu ʻana o kēia mea loaʻa me ka acifran a i ʻole MK-1903 recapulated niacin-induced hoʻomaikaʻi i ka HMVEC tube formation, aʻo GPR109A siRNA i hōʻemi i ka hopena o niacin.Niacin, ma kahi haʻahaʻa haʻahaʻa, hoʻomaikaʻi i ka HMVEC angiogenic hana ma lalo o nā kūlana lipotoxic, kūʻokoʻa paha i ka NAD( +) biosynthesis a me ka hoʻoulu ʻana o SIRT1, akā ma o ka hoʻoulu ʻana i ka mea hoʻokipa niacin.